US 12,454,701 B2
Recombinant adeno-associated viral vector for gene delivery
Timothy J. Miller, New York, NY (US); and Linas Padegimas, Mayfield, OH (US)
Assigned to Abeona Therapeutics Inc., Cleveland, OH (US)
Appl. No. 17/299,434
Filed by Abeona Therapeutics Inc., New York, NY (US)
PCT Filed Dec. 4, 2019, PCT No. PCT/US2019/064396
§ 371(c)(1), (2) Date Jun. 3, 2021,
PCT Pub. No. WO2020/117898, PCT Pub. Date Jun. 11, 2020.
Claims priority of provisional application 62/914,856, filed on Oct. 14, 2019.
Claims priority of provisional application 62/863,126, filed on Jun. 18, 2019.
Claims priority of provisional application 62/801,195, filed on Feb. 5, 2019.
Claims priority of provisional application 62/775,871, filed on Dec. 5, 2018.
Prior Publication US 2022/0090129 A1, Mar. 24, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C12N 9/26 (2006.01); C12N 9/40 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 48/0058 (2013.01); C07K 14/005 (2013.01); C07K 14/4712 (2013.01); C07K 14/705 (2013.01); C12N 9/2411 (2013.01); C12N 9/2465 (2013.01); C12Y 302/0102 (2013.01); C12Y 302/01022 (2013.01); C12N 2750/14122 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01)] 25 Claims
 
1. A nucleic acid encoding an AAV capsid protein comprising a VP1 portion, a VP2 portion, and a VP3 portion, wherein the VP3 portion comprises the amino acid sequence of SEQ ID NO: 41.